Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention
Abstract Introduction In clinical practice, the dose of bivalirudin may not be fully applicable to the Chinese population. Therefore, this study aimed to explore the efficacy and safety of a reduced dose (80% of the recommended dose) of bivalirudin without post-procedure infusion for 3–4 h in patien...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-024-04399-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112866187345920 |
|---|---|
| author | Qian Wang Yan Liu Lin Yang Tienan Zhou Quanyu Zhang Zhiqiang Zhang Dongyuan Sun Xiaozeng Wang |
| author_facet | Qian Wang Yan Liu Lin Yang Tienan Zhou Quanyu Zhang Zhiqiang Zhang Dongyuan Sun Xiaozeng Wang |
| author_sort | Qian Wang |
| collection | DOAJ |
| description | Abstract Introduction In clinical practice, the dose of bivalirudin may not be fully applicable to the Chinese population. Therefore, this study aimed to explore the efficacy and safety of a reduced dose (80% of the recommended dose) of bivalirudin without post-procedure infusion for 3–4 h in patients with acute coronary syndrome (ACS) undergoing elective percutaneous coronary intervention (PCI). Methods This was a single-center, retrospective study. Patients who met the inclusion criteria and no exclusion criteria were divided into reduced-dose and recommended-dose groups for analysis. Confounders were corrected using propensity score matching. The incidence of net adverse clinical events (NACE), major adverse cardiovascular events (MACE), and Bleeding Academic Research Consortium (BARC) type 2–5 bleeding events were observed 30 days postoperatively. Results In total, 1,590 patients (795 per group) were obtained after propensity score matching. The results after propensity score matching were as follows: The activated clotting time (ACT) after 5 min in the reduced-dose group was 349.37 ± 47.59 s, which was statistically lower than that in the recommended-dose group, 353.12 ± 44.98 s (P = 0.024). There was no significant difference in the proportion of ACT values of ≥ 250 s after 5 min between the two groups (P > 0.05). There were no significant differences in NACE, MACE, and BARC type 2–5 bleeding events between the two groups (5.0% vs. 4.5%, P = 0.638; 0.0% vs. 0.1%, P = 1.000; 0.3% vs. 0.5%, P = 0.687). There were no statistically significant differences in cumulative NACE and cumulative bleeding events between the two groups at 30 days (P = 0.635 and P = 0.716, respectively). Conclusion In patients with UA and NSTEMI undergoing elective PCI, 80% of the recommended dose of bivalirudin without post-procedure infusion can be used for anticoagulation without increasing the risk of thrombosis and bleeding. |
| format | Article |
| id | doaj-art-9e1a98c53c754d31a243c46d15eb44f7 |
| institution | Kabale University |
| issn | 1471-2261 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj-art-9e1a98c53c754d31a243c46d15eb44f72024-12-22T12:13:30ZengBMCBMC Cardiovascular Disorders1471-22612024-12-0124111210.1186/s12872-024-04399-5Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary interventionQian Wang0Yan Liu1Lin Yang2Tienan Zhou3Quanyu Zhang4Zhiqiang Zhang5Dongyuan Sun6Xiaozeng Wang7State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandState Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandState Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandState Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandState Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandState Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandState Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandState Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater CommandAbstract Introduction In clinical practice, the dose of bivalirudin may not be fully applicable to the Chinese population. Therefore, this study aimed to explore the efficacy and safety of a reduced dose (80% of the recommended dose) of bivalirudin without post-procedure infusion for 3–4 h in patients with acute coronary syndrome (ACS) undergoing elective percutaneous coronary intervention (PCI). Methods This was a single-center, retrospective study. Patients who met the inclusion criteria and no exclusion criteria were divided into reduced-dose and recommended-dose groups for analysis. Confounders were corrected using propensity score matching. The incidence of net adverse clinical events (NACE), major adverse cardiovascular events (MACE), and Bleeding Academic Research Consortium (BARC) type 2–5 bleeding events were observed 30 days postoperatively. Results In total, 1,590 patients (795 per group) were obtained after propensity score matching. The results after propensity score matching were as follows: The activated clotting time (ACT) after 5 min in the reduced-dose group was 349.37 ± 47.59 s, which was statistically lower than that in the recommended-dose group, 353.12 ± 44.98 s (P = 0.024). There was no significant difference in the proportion of ACT values of ≥ 250 s after 5 min between the two groups (P > 0.05). There were no significant differences in NACE, MACE, and BARC type 2–5 bleeding events between the two groups (5.0% vs. 4.5%, P = 0.638; 0.0% vs. 0.1%, P = 1.000; 0.3% vs. 0.5%, P = 0.687). There were no statistically significant differences in cumulative NACE and cumulative bleeding events between the two groups at 30 days (P = 0.635 and P = 0.716, respectively). Conclusion In patients with UA and NSTEMI undergoing elective PCI, 80% of the recommended dose of bivalirudin without post-procedure infusion can be used for anticoagulation without increasing the risk of thrombosis and bleeding.https://doi.org/10.1186/s12872-024-04399-5Acute coronary syndromeBivalirudinPercutaneous coronary interventionReduced-doseActivated clotting time |
| spellingShingle | Qian Wang Yan Liu Lin Yang Tienan Zhou Quanyu Zhang Zhiqiang Zhang Dongyuan Sun Xiaozeng Wang Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention BMC Cardiovascular Disorders Acute coronary syndrome Bivalirudin Percutaneous coronary intervention Reduced-dose Activated clotting time |
| title | Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention |
| title_full | Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention |
| title_fullStr | Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention |
| title_full_unstemmed | Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention |
| title_short | Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention |
| title_sort | reduced dose of bivalirudin without the post procedure infusion in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention |
| topic | Acute coronary syndrome Bivalirudin Percutaneous coronary intervention Reduced-dose Activated clotting time |
| url | https://doi.org/10.1186/s12872-024-04399-5 |
| work_keys_str_mv | AT qianwang reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention AT yanliu reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention AT linyang reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention AT tienanzhou reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention AT quanyuzhang reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention AT zhiqiangzhang reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention AT dongyuansun reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention AT xiaozengwang reduceddoseofbivalirudinwithoutthepostprocedureinfusioninpatientswithacutecoronarysyndromeundergoingelectivepercutaneouscoronaryintervention |